CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $372,000 | +4.5% | 5,700 | -2.6% | 0.02% | +4.5% |
| Q2 2022 | $356,000 | -3.3% | 5,850 | -0.2% | 0.02% | +46.7% |
| Q1 2022 | $368,000 | -22.7% | 5,860 | -6.6% | 0.02% | -11.8% |
| Q4 2021 | $476,000 | -41.5% | 6,275 | -13.7% | 0.02% | -46.9% |
| Q3 2021 | $814,000 | -58.2% | 7,275 | -39.5% | 0.03% | -57.9% |
| Q2 2021 | $1,947,000 | +114.4% | 12,025 | +61.4% | 0.08% | +100.0% |
| Q1 2021 | $908,000 | -9.5% | 7,450 | +13.7% | 0.04% | -15.6% |
| Q4 2020 | $1,003,000 | +110.3% | 6,550 | +14.9% | 0.04% | +87.5% |
| Q3 2020 | $477,000 | +8.2% | 5,700 | -5.0% | 0.02% | -4.0% |
| Q2 2020 | $441,000 | -87.3% | 6,000 | -92.7% | 0.02% | -91.5% |
| Q1 2020 | $3,462,000 | +440.9% | 81,642 | +677.5% | 0.30% | +821.9% |
| Q4 2019 | $640,000 | +119.9% | 10,500 | +47.9% | 0.03% | +100.0% |
| Q3 2019 | $291,000 | -17.6% | 7,100 | -5.3% | 0.02% | -15.8% |
| Q2 2019 | $353,000 | – | 7,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |